{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:34:01Z","timestamp":1791221641344,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2000,4]]},"DOI":"10.1006\/exnr.2000.7350","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:46:56Z","timestamp":1032191216000},"page":"321-327","source":"Crossref","is-referenced-by-count":216,"title":["Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys"],"prefix":"10.1006","volume":"162","author":[{"given":"Tomoyuki","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K.B.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/exnr.2000.7350_RF1","first-page":"1","article-title":"Overview of morphological changes in Parkinson's disease","volume":"45","author":"Jellinger","year":"1987","journal-title":"Adv. Neurol."},{"key":"10.1006\/exnr.2000.7350_RF2","first-page":"19","article-title":"Biochemical pathophysiology of Parkinson's disease","volume":"45","author":"Hornykiewicz","year":"1987","journal-title":"Adv. Neurol."},{"key":"10.1006\/exnr.2000.7350_RF3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-2008-1041416","article-title":"Practical therapy of Parkinson's disease","volume":"7","author":"Kurlan","year":"1987","journal-title":"Semin. Neurol."},{"key":"10.1006\/exnr.2000.7350_RF4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ana.410250521","article-title":"Pathogenesis of dyskinesias in Parkinson's disease","volume":"25","author":"Mouradian","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.2000.7350_RF5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.50.5_Suppl_5.S3","article-title":"COMT inhibition: A new treatment strategy for Parkinson's disease","volume":"50","author":"Kurth","year":"1998","journal-title":"Neurology"},{"key":"10.1006\/exnr.2000.7350_RF6","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1212\/WNL.50.5_Suppl_5.S26","article-title":"Influence of COMT inhibition on levodopa pharmacology and therapy","volume":"50","author":"Goetz","year":"1998","journal-title":"Neurology"},{"key":"10.1006\/exnr.2000.7350_RF7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s004150050209","article-title":"The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa\/carbidopa formulation","volume":"245","author":"Jorga","year":"1998","journal-title":"J. Neurol."},{"key":"10.1006\/exnr.2000.7350_RF8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","volume":"42","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.2000.7350_RF9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen-Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1006\/exnr.2000.7350_RF10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00734999","article-title":"Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines","volume":"3","author":"Daly","year":"1983","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1006\/exnr.2000.7350_RF11","first-page":"331","article-title":"Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes","volume":"29","author":"Bruns","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"10.1006\/exnr.2000.7350_RF12","first-page":"143","article-title":"Nomenclature and classification of purinoceptors","volume":"46","author":"Fredholm","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1006\/exnr.2000.7350_RF13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-2999(89)90571-2","article-title":"Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680","volume":"168","author":"Jarvis","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1006\/exnr.2000.7350_RF14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(91)90391-6","article-title":"Distribution of adenosine A2 receptor mRNA in the human brain","volume":"130","author":"Schiffmann","year":"1989","journal-title":"Neurosci. Lett."},{"key":"10.1006\/exnr.2000.7350_RF15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1991.tb08257.x","article-title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study","volume":"57","author":"Schiffmann","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1006\/exnr.2000.7350_RF16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0304-3940(91)90387-9","article-title":"Stimulation of adenosine A2 receptors induces catalepsy","volume":"130","author":"Ferre","year":"1991","journal-title":"Neurosci. Lett."},{"key":"10.1006\/exnr.2000.7350_RF17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-2999(94)90551-7","article-title":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity","volume":"256","author":"Kanda","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1006\/exnr.2000.7350_RF18","first-page":"48","article-title":"Action of caffeine and theophyllamine on supersensitive dopamine receptors: Considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists","volume":"52","author":"Fuxe","year":"1974","journal-title":"Med. Biol."},{"key":"10.1006\/exnr.2000.7350_RF19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF02244078","article-title":"Striatal A2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation","volume":"103","author":"Brown","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1006\/exnr.2000.7350_RF20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0091-3057(91)90403-O","article-title":"Behavioral effects of intrastriatal caffeine mediated by adenosinergic modulation of dopamine","volume":"39","author":"Josselyn","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1006\/exnr.2000.7350_RF21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF02244956","article-title":"Adenosine A2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation","volume":"111","author":"Vellucci","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1006\/exnr.2000.7350_RF22","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1021\/jm00090a027","article-title":"(E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: Potent and selective adenosine A2 antagonists","volume":"35","author":"Shimada","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1006\/exnr.2000.7350_RF23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0922-4106(94)90159-7","article-title":"KF17837((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist","volume":"267","author":"Nonaka","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1006\/exnr.2000.7350_RF24","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/S0960-894X(97)00440-X","article-title":"(E)-1,3-Diethyl-8-(3,4-dimethoxystyryl)-7-methylxanthine: A potent adenosine A2 antagonist with anti-cataleptic activity","volume":"7","author":"Shimada","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1006\/exnr.2000.7350_RF25","first-page":"507","article-title":"Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann","volume":"43","author":"Kanda","year":"1998","journal-title":"Neurol."},{"key":"10.1006\/exnr.2000.7350_RF26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02245479","article-title":"Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP treated common marmosets","volume":"109","author":"Loschmann","year":"1992","journal-title":"Psychopharmacology"},{"key":"10.1006\/exnr.2000.7350_RF27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic l-DOPA administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Move. Disord."},{"key":"10.1006\/exnr.2000.7350_RF28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF02246102","article-title":"Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset","volume":"117","author":"Gnanalingham","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1006\/exnr.2000.7350_RF29","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1097\/00001756-199808240-00032","article-title":"Adenosine A2A receptors modify motor function in MPTP-treated common marmosets","volume":"9","author":"Kanda","year":"1998","journal-title":"Neuroreport"},{"key":"10.1006\/exnr.2000.7350_RF30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0306-4522(91)90038-P","article-title":"Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease","volume":"42","author":"Martines-Mir","year":"1991","journal-title":"Neuroscience"},{"key":"10.1006\/exnr.2000.7350_RF31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0165-6147(97)90660-X","article-title":"Adenosine A2A antagonists as new agents for the treatment of Parkinsona's disease","volume":"18","author":"Richardson","year":"1997","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1006\/exnr.2000.7350_RF32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1476-5381.1994.tb16171.x","article-title":"Inhibition by KF17837 of adenosine A2a receptor-mediated modulation of striatal GABA and ACh release","volume":"113","author":"Kurokawa","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1006\/exnr.2000.7350_RF33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1523\/JNEUROSCI.16-02-00605.1996","article-title":"The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons","volume":"16","author":"Mori","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1006\/exnr.2000.7350_RF34","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.66051882.x","article-title":"Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo","volume":"66","author":"Kurokawa","year":"1996","journal-title":"J. Neurochem."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488600973503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488600973503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T09:09:44Z","timestamp":1576487384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488600973503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["S0014488600973503"],"URL":"https:\/\/doi.org\/10.1006\/exnr.2000.7350","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}